首页 › 三阴性乳腺癌 › 明尼苏达州 › Minneapolis
Minneapolis MN 三阴性乳腺癌临床试验
8项针对 三阴性乳腺癌的研究正在 Minneapolis及周边约 30 英里内的站点招募参与者。打开研究详情可查看入选标准及联系研究团队的方式。
官方研究文本（英文）
正在为研究招募参与者？将此页面置顶展示 — $99 / 30天 →
PRE-ISPY Phase I/II Oncology Platform Program
招募中1/2 期
- University of Minnesota Masonic Cancer Center, Minneapolis
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
招募中3 期
- Allina Health Cancer Institute ( Site 0069), Minneapolis
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
招募中3 期
- Metro-Minnesota Community Clinical Oncology ( Site 0031), Saint Louis Park · 距离 5 英里
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
招募中3 期
- Virginia Piper Cancer Center (Allina Health), Minneapolis
- University of Minnesota Medical Center, Fairview, Minneapolis
- Metro Minnesota Community Oncology, Saint Louis Park · 距离 5 英里
A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
招募中1 期
- Normunity Investigational Site, Minneapolis
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
招募中2/3 期
- Local Institution - 0372, Minneapolis
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
招募中1 期
- M Health Fairview University of Minnesota Medical Center - East Bank /ID# 276200, Minneapolis
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
招募中2 期
- University of Minnesota, Minneapolis
- Metro Minnesota Community Oncology Research Consortium, Hennepin County Medical Center, Saint Louis Park · 距离 5 英里
其他城市的 三阴性乳腺癌试验
- Houston, TX42 项研究
- New York City, NY31 项研究
- Nashville, TN28 项研究
- Los Angeles, CA27 项研究
- Boston, MA26 项研究
- San Antonio, TX23 项研究
- St. Louis, MO21 项研究
- Arlington, VA20 项研究
- Atlanta, GA20 项研究
- Dallas, TX18 项研究
- Chicago, IL16 项研究
- Columbus, OH16 项研究
Minneapolis的其他研究
- 非小细胞肺癌27 项研究
- 乳腺癌27 项研究
- 卵巢癌24 项研究
- 前列腺癌23 项研究
- 癌症（所有类型）22 项研究
- 心力衰竭21 项研究
- 急性髓系白血病20 项研究
- 肺癌20 项研究
- 结直肠癌19 项研究
- 子宫内膜癌18 项研究
- 帕金森病17 项研究
- 心血管疾病15 项研究
数据来自 ClinicalTrials.gov，检索日期：2026年10月6日。每项研究自行设定入选标准，由研究团队决定谁能参与。